Your browser doesn't support javascript.
loading
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Campo, Elias; Jaffe, Elaine S; Cook, James R; Quintanilla-Martinez, Leticia; Swerdlow, Steven H; Anderson, Kenneth C; Brousset, Pierre; Cerroni, Lorenzo; de Leval, Laurence; Dirnhofer, Stefan; Dogan, Ahmet; Feldman, Andrew L; Fend, Falko; Friedberg, Jonathan W; Gaulard, Philippe; Ghia, Paolo; Horwitz, Steven M; King, Rebecca L; Salles, Gilles; San-Miguel, Jesus; Seymour, John F; Treon, Steven P; Vose, Julie M; Zucca, Emanuele; Advani, Ranjana; Ansell, Stephen; Au, Wing-Yan; Barrionuevo, Carlos; Bergsagel, Leif; Chan, Wing C; Cohen, Jeffrey I; d'Amore, Francesco; Davies, Andrew; Falini, Brunangelo; Ghobrial, Irene M; Goodlad, John R; Gribben, John G; Hsi, Eric D; Kahl, Brad S; Kim, Won-Seog; Kumar, Shaji; LaCasce, Ann S; Laurent, Camille; Lenz, Georg; Leonard, John P; Link, Michael P; Lopez-Guillermo, Armando; Mateos, Maria Victoria; Macintyre, Elizabeth; Melnick, Ari M.
Afiliação
  • Campo E; Haematopathology Section, Hospital Clínic of Barcelona, Institut d'Investigaciones Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Centro de Investigación Biomédica en Red de Cancer (CIBERONC), Barcelona, Spain.
  • Jaffe ES; Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
  • Cook JR; Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.
  • Quintanilla-Martinez L; Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
  • Swerdlow SH; Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA.
  • Anderson KC; Dana-Farber Cancer Institute, Boston, MA.
  • Brousset P; Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole, and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France.
  • Cerroni L; Department of Dermatology, Medical University of Graz, Graz, Austria.
  • de Leval L; Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
  • Dirnhofer S; Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Dogan A; Laboratory of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Feldman AL; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
  • Fend F; Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
  • Friedberg JW; Wilmot Cancer Institute, University of Rochester, Rochester, NY.
  • Gaulard P; Department of Pathology, University Hospital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France.
  • Ghia P; Mondor Institute for Biomedical Research, INSERM U955, Faculty of Medicine, University of Paris-Est Créteil, Créteil, France.
  • Horwitz SM; Strategic Research Program on Chronic Lymphocytic Leukemia, Division of Experimental Oncology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy.
  • King RL; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Salles G; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
  • San-Miguel J; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Seymour JF; Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, CIBERONC, Pamplona, Spain.
  • Treon SP; Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Vose JM; Dana-Farber Cancer Institute, Boston, MA.
  • Zucca E; Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, University of Nebraska, Omaha, NE.
  • Advani R; Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, and Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland.
  • Ansell S; Stanford Cancer Center, Blood and Marrow Transplant Program, Stanford University, Stanford, CA.
  • Au WY; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
  • Barrionuevo C; Blood-Med Clinic, Hong Kong, People's Republic of China.
  • Bergsagel L; Department of Pathology, Instituto Nacional de Enfermedades Neoplásicas, Faculty of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru.
  • Chan WC; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ.
  • Cohen JI; Department of Pathology, City of Hope National Medical Center, Duarte, CA.
  • d'Amore F; Medical Virology Section, Laboratory of Infectious Diseases, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD.
  • Davies A; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
  • Falini B; Cancer Research UK Centre, Centre for Cancer Immunology, Faculty of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom.
  • Ghobrial IM; Institute of Hematology and Center for Hemato-Oncology Research, Hospital of Perugia, University of Perugia , Perugia, Italy.
  • Goodlad JR; Dana-Farber Cancer Institute, Boston, MA.
  • Gribben JG; Harvard Medical School, Harvard University, Boston, MA.
  • Hsi ED; National Health Service Greater Glasgow and Clyde, Glasgow, United Kingdom.
  • Kahl BS; Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Kim WS; Department of Pathology, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, NC.
  • Kumar S; Oncology Division, Washington University School of Medicine, Washington University in St. Louis, St. Louis, MO.
  • LaCasce AS; Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Laurent C; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
  • Lenz G; Dana-Farber Cancer Institute, Boston, MA.
  • Leonard JP; Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole, and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France.
  • Link MP; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.
  • Lopez-Guillermo A; Weill Department of Medicine, Weill Medical College, Cornell University, New York, NY.
  • Mateos MV; Department of Pediatrics, Division of Pediatric Hematology-Oncology, Stanford University School of Medicine, Stanford University, Stanford, CA.
  • Macintyre E; Department of Hematology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
  • Melnick AM; Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cancer, Universidad de Salamanca, Salamanca, Spain.
Blood ; 140(11): 1229-1253, 2022 09 15.
Article em En | MEDLINE | ID: mdl-35653592
ABSTRACT
Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / Linfoma Tipo de estudo: Diagnostic_studies / Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / Linfoma Tipo de estudo: Diagnostic_studies / Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article